


Vorapaxar

Cat. No.:	HY-10119		
CAS No.:	618385-01-6		
Molecular Formula:	C ₂₉ H ₃₃ FN ₂ O ₄		
Molecular Weight:	492.58		
Target:	Protease Activated Receptor (PAR)		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (50.75 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.0301 mL	10.1506 mL	20.3013 mL
		5 mM		0.4060 mL	2.0301 mL	4.0603 mL
10 mM			0.2030 mL	1.0151 mL	2.0301 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.08 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K _i =8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner ^[1] .
IC₅₀ & Target	Ki: 8.1 nM (PAR-1) ^[1]
In Vitro	Vorapaxar (SCH 530348) shows potent inhibition of thrombin-induced platelet aggregation with an IC ₅₀ of 47 nM and

haTRAP-induced platelet aggregation with an IC_{50} of 25 nM. Vorapaxar (SCH 530348) inhibits thrombin-induced calcium transient in human coronary artery smooth muscle cells (HCASMC) with a K_i of 1.1 nM. It also inhibits thrombin-stimulated thymidine incorporation in HCASMC with a K_i of 13 nM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Dis. 2020 Jul 9;11(7):520.
- J Med Chem. 2017 Aug 24;60(16):7166-7185.
- Biomed Res Int. 2022 Sep 20;2022:8265898.
- Eur J Oral Sci. 2019 Aug;127(4):287-293.
- Mol Med Rep. 2019 Jun;19(6):5291-5300.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Khoufache K, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123(1):206-14.

[2]. Kehinde O, et al. Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA